Search for Clinical Trial Results

Sponsored By

Congenital Cytomegalovirus - 25 Studies Found

Status Study
Recruiting Study Name: Diagnosis of Congenital CMV Infection in Neonates Who Failed Newborn Hearing Screening
Condition: Congenital Cytomegalovirus Infection
Date: 2014-04-28
Interventions: Other: CMV PCR Other Name: CMV PCR results are communicated to the relevant clinicians in real time.
Recruiting Study Name: Assesment of Olfactory Disorders and Performance of a New Olfactory Test in Children With Congenital CMV
Condition: Congenital Cytomegalovirus Infection
Date: 2016-05-23
Interventions: Other: olfactory tests, otoacoustic emissions (OAE) Two series of olfactory tests will be performed : 1)
Terminated Study Name: Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial
Condition:
  • Congenital Cytomegalovirus Infection
  • Sensorineural Hearing Loss
    Date: 2012-07-13
    Interventions: Drug: Valganciclovir Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two
Recruiting Study Name: Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
Condition:
  • Congenital Cytomegalovirus Infection
  • Sensorineural Hearing Loss
    Date: 2013-12-04
    Interventions: Drug: Valganciclovir Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two
Recruiting Study Name: A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
Condition:
  • Congenital Cytomegalovirus Infection
  • Maternal Cytomegalovirus I
    Date: 2011-06-15
    Interventions: Drug: CMV hyperimmune globulin The study's active drug is Cytogam® which is an immunoglobulin G (Ig
Not yet recruiting Study Name: Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance
Condition: Congenital Cytomegalovirus (CMV)
Date: 2015-11-05
Interventions: Drug: Valganciclovir Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension) at a dose of 1
Recruiting Study Name: Congenital CMV and Hearing Loss in Children up to 4 Years of Age: Treating With Valganciclovir Therapy
Condition:
  • Congenital Cytomegalovirus
  • Hearing Loss

Date: 2012-07-20
Interventions:
  • Drug: Valcyte (Valganciclovir hydrochloride) Powder for oral solution

Recruiting Study Name: A Cross-sectional Study of Congenital Cytomegalovirus Infection in Newborns in China
Condition: Congenital Cytomegalovirus Infection
Date: 2016-03-05
Recruiting Study Name: Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy
Condition: Congenital Cytomegalovirus Infection
Date: 2015-01-18
Interventions:
  • Drug: Valacyclovir
  • Drug: Placebo
Withdrawn Study Name: Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine
Condition: Congenital Cytomegalovirus Infection
Date: 2015-10-16
Interventions: Drug: CyMVectin CyMVectin will be delivered by unilateral intramuscular (IM) injection at Day 0, Day 28(
Next >>>